Prognostic factors, treatment decisions, and nomograms for patients with second primary lung cancer following colorectal cancer: a population-based study.
Colorectal cancer
Lung cancer
Nomogram
Prognostic factors
Seer
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
20
05
2023
accepted:
19
07
2023
pubmed:
3
8
2023
medline:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Colorectal cancer (CRC) survival rates continue to improve, but the risk of developing a second primary malignancy (SPM) has also increased. The most common type of SPM observed after CRC is lung cancer. In this study, we explored the prognostic factors and clinical management decisions of patients with second primary lung cancer after colorectal cancer (SPLC-CRC). We identified the data of 1637 patients with SPLC-CRC from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. Cox regression modeling was used to construct a nomogram for predicting the prognosis of SPLC-CRC patients. The Fine-Gray competing risk model was used to determine the association between factors and cancer-specific mortality. After this, survival analyses were performed to assess the benefit of each treatment method on overall survival (OS). According to a multivariate analysis, age, gender, surgery, and chemotherapy were independent prognostic factors for the first primary malignancy (FPM), whereas age, primary site, TNM stage, tumor size, and treatment were independent prognostic factors for the second primary malignancy (SPM). For the training cohort column chart as well as the validation cohort column chart, using the concordance index of OS, 0.7611 and 0.7605 were calculated. A Fine-Gray competing risk model and survival analysis showed that there is a significant correlation between the treatment of FPM and the improvement in SPM survival rates, FPM-diagnosed patients who undergo surgery in different pathological stages exhibit higher overall survival rates, Patients in stages II, III, and IV benefit from combined surgery and chemotherapy. SPM surgery (P < 0.001, HR = 0.230, 95%CI 0.032-0.426) was a protective factor for lung cancer-specific mortality. Patients with local, regional, and even distant metastases may benefit more from SPM surgery (P < 0.001, P < 0.001, and P < 0.001, respectively). In patients who did not undergo SPM surgery, radiotherapy (P < 0.001) and chemotherapy (P = 0.008) improved OS. Treatment strategy for the first tumor affects the prognosis of the second tumor significantly. SPLC-CRC is treated primarily with surgery, regardless of whether the patient has metastases, as surgery may improve outcomes. In the event that a patient is unable to undergo surgery, chemotherapy or radiotherapy should be considered. Treatment decisions for SPLC-CRC patients may be influenced by these findings.
Identifiants
pubmed: 37535188
doi: 10.1007/s13304-023-01605-5
pii: 10.1007/s13304-023-01605-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1827-1842Subventions
Organisme : Chinese Medicine Inheritance Innovation Platform Construction Project (State Administration of Traditional Chinese Medicine Base Construction Stomach Cancer Special Fund)
ID : Y2020CS57
Informations de copyright
© 2023. Italian Society of Surgery (SIC).
Références
Zheng X, Li X, Wang M, Shen J, Sisti G, He Z, Huang J, Li YM, Wu A, Multidisciplinary Oncology Research Collaborative Group (MORCG) (2020) Second primary malignancies among cancer patients. Ann Transl Med. 8(10):638
doi: 10.21037/atm-20-2059
pubmed: 32566575
pmcid: 7290649
Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48
doi: 10.3322/caac.21763
pubmed: 36633525
Han SS, Rivera GA, Tammemägi MC, Plevritis SK, Gomez SL, Cheng I, Wakelee HA (2017) Risk stratification for second primary lung cancer. J Clin Oncol 35(25):2893–2899
doi: 10.1200/JCO.2017.72.4203
pubmed: 28644772
pmcid: 5946715
Romaszko AM, Doboszyńska A (2018) Multiple primary lung cancer: a literature review. Adv Clin Exp Med 27(5):725–730
doi: 10.17219/acem/68631
pubmed: 29790681
Jia H, Li Q, Yuan J, Sun X, Wu Z (2020) Second primary malignancies in patients with colorectal cancer: a population-based analysis. Oncologist 25(4):e644–e650. https://doi.org/10.1634/theoncologist.2019-0266
doi: 10.1634/theoncologist.2019-0266
pubmed: 31943509
pmcid: 7160402
Chen Y, Han C, Huang Y, Liu C, Sheng S, Ji L, Zhu J, Fu G, Mao X, Huang M, Lei Z, Chu X (2022) The incidence of second primary cancer in male and female patients with initial colorectal cancer: a SEER population-based study. Eur J Cancer Prev 31(5):430–441
doi: 10.1097/CEJ.0000000000000731
pubmed: 34991112
Deng L, Harðardottír H, Song H, Xiao Z, Jiang C, Wang Q, Valdimarsdóttir U, Cheng H, Loo BW, Lu D (2019) Mortality of lung cancer as a second primary malignancy: a population-based cohort study. Cancer Med 8(6):3269–3277
doi: 10.1002/cam4.2172
pubmed: 30993899
pmcid: 6558593
Baird DC, Meyers GJ, Hu JS (2018) Testicular cancer: diagnosis and treatment. Am Fam Physician 97(4):261–268
pubmed: 29671528
Zhou H, Shen J, Zhang Y, Huang Y, Fang W, Yang Y, Hong S, Liu J, Xian W, Zhang Z, Ma Y, Zhou T, Zhao H, Zhang L (2019) Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database. Ann Transl Med 7(18):439
doi: 10.21037/atm.2019.09.01
pubmed: 31700875
pmcid: 6803229
Wittekind C, Klimpfinger M, Hermanek P, Tannapfel A (1997) Multiple simultaneous gastric carcinomas. Br J Cancer 76(12):1604–1609. https://doi.org/10.1038/bjc.1997.604.PMID:9413949;PMCID:PMC2228195
doi: 10.1038/bjc.1997.604.PMID:9413949;PMCID:PMC2228195
pubmed: 9413949
pmcid: 2228195
Donin NM, Kwan L, Lenis AT, Drakaki A, Chamie K (2019) Second primary lung cancer in united states cancer survivors, 1992–2008. Cancer Causes Control CCC 30(5):465–475
doi: 10.1007/s10552-019-01161-7
pubmed: 30900065
Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decision Making 26(6):565–574. https://doi.org/10.1177/0272989X06295361
doi: 10.1177/0272989X06295361
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509. https://doi.org/10.1080/01621459.1999.10474144
doi: 10.1080/01621459.1999.10474144
National Cancer Institute, Surveillance E and End Results Program. SEER*Stat software version 8.3.9 (Accessed March 15, 2021).
Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L et al (2016) Risk of second primary malignancies among cancer survivors in the united states, 1992 through 2008. Cancer 122(19):3075–3086
doi: 10.1002/cncr.30164
pubmed: 27377470
Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J et al (2015) Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 26:463–476
doi: 10.1093/annonc/mdu253
pubmed: 25015334
West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P (2010) Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 28:272–278
doi: 10.1200/JCO.2009.24.1448
pubmed: 19949013
Seymour MT, Morton D (2019) FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 37:3504
doi: 10.1200/JCO.2019.37.15_suppl.3504
Lin X, Li J, Sun Y, Zhang L, Zhang S, Wu H, Ma B, Xu Y (2020) Survival outcomes and risk factors for secondary malignancies after surgery for colorectal cancer: a systematic review and meta-analysis. Cancer Manag Res 12:4639–4651
Hoy H, Lynch T, Beck M (2019) Surgical treatment of lung cancer. Crit Care Nurs Clin North Am 31(3):303–313
doi: 10.1016/j.cnc.2019.05.002
pubmed: 31351552
Thakur MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, Beebe-Dimmer JL, Wozniak AJ (2018) Risk of second lung cancer in patients with previously treated lung cancer: analysis of surveillance, epidemiology, and end results (SEER) data. J Thorac Oncol 13(1):46–53
doi: 10.1016/j.jtho.2017.09.1964
pubmed: 28989038
Billiet C, Chiairi I, Berzenji L, Van Schil PE (2020) Early-stage lung cancer: Is there still a role for surgery? Rev Des Maladies Respiratoires 37(9):735–742
doi: 10.1016/j.rmr.2020.06.018
Kuo CC, Hsieh CC, Wang CK, Lai CC, Chen YY (2017) Surgery for non-small cell lung cancer with distant metastasis at presentation: a population-based study. PLoS ONE 12(6):e0178185
Nitti D, Pesce GA, Bregni M, De Marinis F, Sperduti I, Crinò L, Maione P (2017) Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center study. BMC Cancer 17(1):243
Gao Y, Guan W, Liu J, Wang Y, Li S (2020) The role of postoperative adjuvant chemotherapy in resectable stage IIIA-N2 non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis 12(1):85–94
Huang Y, Li S, Chen X (2019) The efficacy and safety of PD-1/PD-L1 inhibitors combined with chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Cancer Med 8(23):7571–7583
Li G, Li Y, Li X, Li X, Chen X, Liang Z (2019) The efficacy and safety of targeted therapy and immunotherapy in treating advanced non-small cell lung cancer: a network meta-analysis. J Cancer Res Ther 15(6):1251–1260
Bahl A, Sharma DN, Julka PK, Rath GK (2006) Chemotherapy related toxicity in locally advanced non-small cell lung cancer. J Cancer Res Ther 2(1):14–16
doi: 10.4103/0973-1482.19767
pubmed: 17998666
Bradley J, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. J Lancet Oncol 16(2):187–199
doi: 10.1016/S1470-2045(14)71207-0
Gouran-Savadkoohi M, Mesci A, Pond GR, Swaminath A, Quan K, Wright J, Tsakiridis T (2023) Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer. J Thorac Dis 15(2):423–433
doi: 10.21037/jtd-22-925
pubmed: 36910062
pmcid: 9992560
Li M, Li J, Li P, Li H (2017) Gender differences in lung cancer survival: a meta-analysis. J Thorac Oncol 12(2):S327–S328
Tolwin Y, Gillis R, Peled N (2020) Gender and lung cancer-SEER-based analysis. Ann Epidemiol 46:14–19
doi: 10.1016/j.annepidem.2020.04.003
pubmed: 32532368
Radkiewicz C, Dickman PW, Johansson ALV, Wagenius G, Edgren G, Lambe M (2019) Sex and survival in non-small cell lung cancer: a nationwide cohort study. PLoS ONE 14(6):e0219206
doi: 10.1371/journal.pone.0219206
pubmed: 31247015
pmcid: 6597110
Wisnivesky J, Halm EJ (2007) Sex differences in lung cancer survival: do tumors behave differently in elderly women. J Clin Oncol 25(13):1705–1712
doi: 10.1200/JCO.2006.08.1455
pubmed: 17470862
Radzikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 13(7):1087–1093
doi: 10.1093/annonc/mdf187
pubmed: 12176788
Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC et al (2016) Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun 7:11762
doi: 10.1038/ncomms11762
pubmed: 27272654
pmcid: 4899869
Iversen S (1954) Human cancer and age. Br J Cancer 8(4):575–584
doi: 10.1038/bjc.1954.62
pubmed: 14351598
pmcid: 2007970
Owonikoko T, Ragin C, Belani C, Oton AB, Gooding WE, Taioli E et al (2007) Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25(35):5570–5577
doi: 10.1200/JCO.2007.12.5435
pubmed: 18065729